BMS-754807

Name: BMS-754807
Brand: Selleck Chemicals
SKU: S1124
Rating: 5 (27 reviews)

For research use only.

Catalog No.S1124

27 publications

CAS No. 1001350-96-4

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Selleck's BMS-754807 has been cited by 27 publications

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2485

PubMed: 31969334 ( click the link to review the publication )

Sci Signal, 2020, 26;13(633):eaba3176

PubMed: 32457113 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

Cell Rep, 2019, 28(12):3224-3237

PubMed: 31533043 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):619-630

PubMed: 30956007 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

Drug Deliv, 2018, 25(1):241-255

PubMed: 29334272 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Genes Dev, 2017, 31(6):553-566

PubMed: 28404630 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29099049 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )
PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	M4DoU2tqdmG\|ZTDhd5NigQ>?			NGK2SJZqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFnHSk0yWiBqSVO1NEA:KDF\|bl2pJIFv\CC2aHWg[I94dnO2cnXhcUB1[XKpZYTzJGFsfCBqSVO1NEA:KDJ{bl2pJIFv\CCPQWDLJEhKSzVyIE2gNVNvVSl?	MVOxPVc4QDB{NB?=
IGF-Sal	M2iyOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7			MnO3TWM2OD15IH7N	NXf1VlJCOTl5N{iwNlQ>
CCRF-CEM (ALL)	M4e3RWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGi1OpB,PSEQvF2=	M{mwOGROW09?	M{nnSWlEPTB;MT6yN\|kh\|ryP	Mne0NVk6QTZ{N{K=
PC3	MljES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVP+OUDPxE1?	MXHEUXNQ	NFP3dWpKSzVyPUCuPVY2KM7:TR?=	NFy2VXMyQTl7NkK3Ni=>
JD	M4fG[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmjGglUh\|ryP	NWKyXJd6TE2VTx?=	MWPJR\|UxRTBwM{mxJO69VQ>?	M1fLWVE6QTl4Mkey
DU145	Mof4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2PMWp42KM7:TR?=	MWXEUXNQ	MkexTWM2OD1zLkS2OUDPxE1?	MUOxPVk6PjJ5Mh?=
KAG	MlXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3fiZ542KM7:TR?=	MYTEUXNQ	MXLJR\|UxRTFwNk[1JO69VQ>?	NGiweJYyQTl7NkK3Ni=>
K-562 (CML)	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NULxb2IyhjVizszN	NIryV4FFVVOR	Mm\iTWM2OD1{LkOwNkDPxE1?	NYewSJhKOTl7OU[yO\|I>
B6-P210 (Murine ALL)	NYexeXFNT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnXuglUh\|ryP	MXXEUXNQ	NGDzZ5hKSzVyPUGuNlk{KM7:TR?=	MoD1NVk6QTZ{N{K=
LN CAP-FGC	NHXoSWxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M17OXZ42KM7:TR?=	NVzrPYRYTE2VTx?=	NWKySlMxUUN3ME2xMlQ{PCEQvF2=	NEXVSnkyQTl7NkK3Ni=>
VW	NEHjbGhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoLtglUh\|ryP	NV;qfmRUTE2VTx?=	NXTyWYRUUUN3ME2wMlAyQSEQvF2=	MmLPNVk6QTZ{N{K=
MV411 (B Myelomonocytic)	NWWyfoVYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGnIdZR,PSEQvF2=	NGnkOpJFVVOR	NEi5PIZKSzVyPUCuN\|Mh\|ryP	NIKw[mQyQTl7NkK3Ni=>
MDA-PCa-2b	MmL2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlnCglUh\|ryP	NUDjUmFJTE2VTx?=	NWr2OXE3UUN3ME2wMlA6QCEQvF2=	NYnucJRyOTl7OU[yO\|I>
LG	M4i3dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIDESHJ,PSEQvF2=	M4j2dmROW09?	MW\JR\|UxRTBwMEO4JO69VQ>?	NU\mWoY1OTl7OU[yO\|I>
RS411 (B cell precursor-ALL)	NHixfGxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUG3[llnhjVizszN	M4D0WGROW09?	MkfxTWM2OD1yLkGwNkDPxE1?	MXWxPVk6PjJ5Mh?=
22-r-1	MnnVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoW0glUh\|ryP	NGrOfGZFVVOR	MXTJR\|UxRTBwMUe1JO69VQ>?	MlHlNVk6QTZ{N{K=
5838	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXO2blMxhjVizszN	M1TFeWROW09?	MmfsTWM2OD1yLkCzOEDPxE1?	NFTl[moyQTl7NkK3Ni=>
P388 (Murine)	NWH6Vpc3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX3+OUDPxE1?	NUDvSJVLTE2VTx?=	M1rTO2lEPTB;ND6yO{DPxE1?	NHPhfVIyQTl7NkK3Ni=>
A2780/S	M13mN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIXKemZ,PSEQvF2=	NYrFV\|cyTE2VTx?=	MXzJR\|UxRTBwMUKyJO69VQ>?	NYX2VGJ5OTl7OU[yO\|I>
RDES	MmPHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NH3USIN,PSEQvF2=	NV[0T3E5TE2VTx?=	NGrWNnNKSzVyPUCuNFEzKM7:TR?=	NYi2SWtROTl7OU[yO\|I>
B6-T315I (Murine B-ALL)	Mof6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NF3ObIN,PSEQvF2=	NFLUU21FVVOR	NILBSGlKSzVyPUKuPFMh\|ryP	MorjNVk6QTZ{N{K=
TOV 112D	Mkj6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1nNTp42KM7:TR?=	MkP3SG1UVw>?	MXrJR\|UxRTJwMUS2JO69VQ>?	NHrWS5MyQTl7NkK3Ni=>
TC32	NV7ERVlrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEHkcWp,PSEQvF2=	NW\EUGVZTE2VTx?=	MWnJR\|UxRTBwMEC4JO69VQ>?	M{nwSlE6QTl4Mkey
HL60 (acute myelocytic)	NWPs[JlrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3T3Rp42KM7:TR?=	M2\LeWROW09?	NW\3[npvUUN3ME2wMlEzKM7:TR?=	MXexPVk6PjJ5Mh?=
TOV 21G	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlmyglUh\|ryP	NH;leFJFVVOR	MYHJR\|UxRTRwMke5JO69VQ>?	MoLTNVk6QTZ{N{K=
TC71	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVLQU4dlhjVizszN	NUPtRol3TE2VTx?=	M1rE[GlEPTB;MD6wNVQh\|ryP	M{j3TFE6QTl4Mkey
HPN-ALL (T-cell)	M{XkSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NE[yepl,PSEQvF2=	NWe2SYs6TE2VTx?=	M1XqVGlEPTB;MD61NkDPxE1?	M333R\|E6QTl4Mkey
A2780R	NXK3O4J7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmnPglUh\|ryP	NXvQ[FltTE2VTx?=	Mlm4TWM2OD1zLkW2OEDPxE1?	NHzTVlAyQTl7NkK3Ni=>
Rh1	MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkSyglUh\|ryP	MlnCSG1UVw>?	NVTxc25XUUN3ME2wMlAzPyEQvF2=	M1\KOFE6QTl4Mkey
Kasumi-1 (acute myeloid)	Ml\RS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUj+OUDPxE1?	MU\EUXNQ	NHHZWo5KSzVyPUCuNVYh\|ryP	MmW0NVk6QTZ{N{K=
sk-ov-3	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIHpeoN,PSEQvF2=	NXvkZ\|BqTE2VTx?=	M37uT2lEPTB;NT6xJO69VQ>?	NWi0SZBROTl7OU[yO\|I>
ME	M{TlRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH;2V4J,PSEQvF2=	Mn7rSG1UVw>?	MlnZTWM2OD1yLkCxOUDPxE1?	M4fRelE6QTl4Mkey
L1210 (Murine lymphocytic)	MnXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MW\+OUDPxE1?	MWjEUXNQ	MoToTWM2OD1{LkO5JO69VQ>?	M2DCfVE6QTl4Mkey
sw-626	NUexVpFwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH3UUYd,PSEQvF2=	NGnCVFdFVVOR	NHzt[G1KSzVyPUKuN\|A3KM7:TR?=	MlTtNVk6QTZ{N{K=
CTR	NEfpVFZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3;Nb542KM7:TR?=	MkXPSG1UVw>?	NHfhbI9KSzVyPUCuNlU{KM7:TR?=	NEW2TIwyQTl7NkK3Ni=>
ML2 (Myelomonocytic)	M2TO[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmDBglUh\|ryP	NIWyOlhFVVOR	M{PrXWlEPTB;MD6wPUDPxE1?	MlnyNVk6QTZ{N{K=
ovcar-3	NX[wfo5RT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXj+OUDPxE1?	MorjSG1UVw>?	NVzUb3JDUUN3ME21JO69VQ>?	NVTnXmp4OTl7OU[yO\|I>
Rh36	MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mn;RglUh\|ryP	NU\DXZlLTE2VTx?=	NIDMV45KSzVyPUGuOFMzKM7:TR?=	MkTMNVk6QTZ{N{K=
MOLM-13 (acute myeloid)	M2W2Xmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NI\5V\|R,PSEQvF2=	M3Wx[mROW09?	M2nyb2lEPTB;MD60NkDPxE1?	MmDBNVk6QTZ{N{K=
ovcar-4	NI\HWGJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWf6PVNuhjVizszN	MmiwSG1UVw>?	NYDjc\|V2UUN3ME2xJO69VQ>?	MnP5NVk6QTZ{N{K=
Rh41	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXvCdGRmhjVizszN	MXrEUXNQ	MVnJR\|UxRTBwMEC1JO69VQ>?	MVOxPVk6PjJ5Mh?=
Mutz 2 (acute myeloid)	MmTsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlXlglUh\|ryP	MlnxSG1UVw>?	M3nKVGlEPTB;MT6xOUDPxE1?	NVjaWpEyOTl7OU[yO\|I>
ovcar-5	M{j5Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH3wfVJ,PSEQvF2=	NWLGcm52TE2VTx?=	MWnJR\|UxRTBwMEWg{txO	MXuxPVk6PjJ5Mh?=
RD1	NETmZZBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{e4ep42KM7:TR?=	NXnic5l7TE2VTx?=	NX\tZZkzUUN3ME2wMlA3QCEQvF2=	NYHYem4xOTl7OU[yO\|I>
OCI-AML 2 (acute myeloid)	M1\lVmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NULKeodphjVizszN	MlrRSG1UVw>?	NFjNdmpKSzVyPUOuN\|Mh\|ryP	NHjGRZYyQTl7NkK3Ni=>
786-O	NWX0V2x7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mn;GglUh\|ryP	MUXEUXNQ	M2rNR2lEPTB;MT62OFch\|ryP	MlvTNVk6QTZ{N{K=
A673	NV\leFd4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NELLXZh,PSEQvF2=	M33KbWROW09?	NVfNc\|VOUUN3ME2wMlQxQCEQvF2=	NXnu[WN6OTl7OU[yO\|I>
TALL-1 (T-cell)	NHHBNoxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MV7+OUDPxE1?	MX7EUXNQ	M4nHdmlEPTB;MT6yPEDPxE1?	NHrTd4cyQTl7NkK3Ni=>
151-B	NXL5U3FFT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXuwToVrhjVizszN	NEmxPJlFVVOR	M4q2fWlEPTB;Mj62O{DPxE1?	M1;TN\|E6QTl4Mkey
PFSK-1	NUf2RXNST3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4n0N542KM7:TR?=	NILCUmpFVVOR	MV7JR\|UxRTBwMUOyJO69VQ>?	MnTGNVk6QTZ{N{K=
THP-1	NF24[IRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MonTglUh\|ryP	NXLYdWdwTE2VTx?=	NYDlWJY3UUN3ME22MlU5KM7:TR?=	MmS2NVk6QTZ{N{K=
HEK293	NWfSSmhCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHXacXl,PSEQvF2=	NVWxZnpVTE2VTx?=	MXTJR\|UxRTBwOUG1JO69VQ>?	M{XtNVE6QTl4Mkey
DAOY	NFna[HlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1fOZp42KM7:TR?=	M3jZdWROW09?	NGrvelJKSzVyPUGuPVc6KM7:TR?=	NGm2bmsyQTl7NkK3Ni=>
SET2	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4fTNZ42KM7:TR?=	M4TkUGROW09?	NVTMbHlLUUN3ME2wMlI6QCEQvF2=	MXqxPVk6PjJ5Mh?=
HTB-46	M4TsV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3H0PJ42KM7:TR?=	M2rKXGROW09?	MlnITWM2OD13LkK1JO69VQ>?	NGfrd4gyQTl7NkK3Ni=>
SK-NAS	M4\Tdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkXBglUh\|ryP	M4LvVmROW09?	M1rRbmlEPTB;MD60PVch\|ryP	MUGxPVk6PjJ5Mh?=
CTLL2	NI\PUVlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXjCVHl4hjVizszN	MkHsSG1UVw>?	NHXIOXhKSzVyPkGuNFAh\|ryP	NFu0WpIyQTl7NkK3Ni=>
HTB-47	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHKzTHN,PSEQvF2=	MoPXSG1UVw>?	NGTDc21KSzVyPUKuNFU3KM7:TR?=	NVO3[24yOTl7OU[yO\|I>
LAN-1	MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGnlbnh,PSEQvF2=	MVHEUXNQ	NUD6RW5QUUN3ME2wMlA1KM7:TR?=	MkjuNVk6QTZ{N{K=
ST486	MnXrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVj+OUDPxE1?	NEX2ZYJFVVOR	M3vWTmlEPTB;MT6xPUDPxE1?	NXXE[3VKOTl7OU[yO\|I>
HS766T	MoLFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUP+OUDPxE1?	NYL0[VA6TE2VTx?=	MYXJR\|UxRTJwMECxJO69VQ>?	MXuxPVk6PjJ5Mh?=
IMR-32	MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIXLW2F,PSEQvF2=	M4T2ZmROW09?	NHrXOZRKSzVyPUCuNlYyKM7:TR?=	NWDM[WVVOTl7OU[yO\|I>
Daudi (Burkitt's)	NFHM[mNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MX\+OUDPxE1?	M{\MUWROW09?	NYrvbJdYUUN3ME2yMlY{PyEQvF2=	MnzzNVk6QTZ{N{K=
Aspc-1	MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXTnU5VyhjVizszN	MYLEUXNQ	MmK5TWM2OD1yLkO3PUDPxE1?	NGrvXHoyQTl7NkK3Ni=>
SK-NSH	MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnHEglUh\|ryP	NEXldJRFVVOR	NFrZdmNKSzVyPUCuNVM6KM7:TR?=	MkjPNVk6QTZ{N{K=
MEC-1 (Chronic B cell)	M4HSV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVjib4NFhjVizszN	NWL1bZlvTE2VTx?=	NX63ZYZjUUN3ME2yMlY{PyEQvF2=	M1TGcFE6QTl4Mkey
Capan-2	NIrNeJhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoTWglUh\|ryP	M{TCZmROW09?	MWDJR\|UxRTFwN{e0JO69VQ>?	NUe2UIN5OTl7OU[yO\|I>
SHSY5Y	NYO5[WdkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYr+OUDPxE1?	MUHEUXNQ	NHL5cVhKSzVyPUCuNVA3KM7:TR?=	MVKxPVk6PjJ5Mh?=
U937 (Histioocytic)	NV65e3p{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFjmeJh,PSEQvF2=	M2q2RmROW09?	M4nsW2lEPTB-NT6wNEDPxE1?	MVmxPVk6PjJ5Mh?=
Bxpc-1	MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NV32VINWhjVizszN	MXXEUXNQ	NY\zTVB5UUN3ME2xMlkzPCEQvF2=	MnPHNVk6QTZ{N{K=
Bxpc-3	MmPaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVv+OUDPxE1?	NGS3T\|lFVVOR	Mn7nTWM2OD53LkCwJO69VQ>?	NFO2dJoyQTl7NkK3Ni=>
HTB-92	MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1zrdJ42KM7:TR?=	MmP5SG1UVw>?	Ml3CTWM2OD1zLkCyJO69VQ>?	M2LCb\|E6QTl4Mkey
OCI-LY10 (B-cell)	NEDTTVdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFLQOGV,PSEQvF2=	MWrEUXNQ	M1nL[2lEPTB;MD60OUDPxE1?	MVexPVk6PjJ5Mh?=
PANC-1	NIDEdoRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYP+OUDPxE1?	NYGzPYM6TE2VTx?=	NGnWeZNKSzVyPkWuNFAh\|ryP	MX2xPVk6PjJ5Mh?=
To184.T	M{fvSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEXyUmF,PSEQvF2=	M13XSGROW09?	NFv4dXVKSzVyPUCuOFY6KM7:TR?=	NULSbJh3OTl7OU[yO\|I>
OCI-LY19 (B-cell)	NYr6b\|NVT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXu5[ZJ1hjVizszN	MlTNSG1UVw>?	NXj4OIdrUUN3ME2wMlQh\|ryP	NIXoV5oyQTl7NkK3Ni=>
PANC-1 BM	MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MU\+OUDPxE1?	NXrVPZFvTE2VTx?=	NGfESYJKSzVyPkWuNFAh\|ryP	MlTxNVk6QTZ{N{K=
SA-4	MlzqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MV\+OUDPxE1?	MX\EUXNQ	Ml3CTWM2OD1zLkOwNUDPxE1?	MmjLNVk6QTZ{N{K=
RPMI 8226	M3\HWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmT0glUh\|ryP	M2LPfGROW09?	M3vMOGlEPTB;MT6yPVMh\|ryP	MUmxPVk6PjJ5Mh?=
HPAF-II	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXn+OUDPxE1?	MXHEUXNQ	MmjrTWM2OD1yLk[0OEDPxE1?	NWnHOZZkOTl7OU[yO\|I>
SHP-77	MmDXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYLucng1hjVizszN	NGjDdppFVVOR	M1;nPWlEPTB;MT64PFgh\|ryP	MUGxPVk6PjJ5Mh?=
U266 B1	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHLTW2p,PSEQvF2=	MkXhSG1UVw>?	MlXwTWM2OD1zLk[2PUDPxE1?	M3TrSFE6QTl4Mkey
Hs700t	NG\SVFJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MV7+OUDPxE1?	MVrEUXNQ	NET6XVlKSzVyPUCuNlMyKM7:TR?=	NVTJc2tvOTl7OU[yO\|I>
NCI-446	M1Gydmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mme2glUh\|ryP	M1\ZWGROW09?	NESye5FKSzVyPUGuNVU1KM7:TR?=	MnG0NVk6QTZ{N{K=
H929	MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFv1RWR,PSEQvF2=	M1nTSWROW09?	MmjiTWM2OD1yLkCxOEDPxE1?	NGLseYEyQTl7NkK3Ni=>
PL45	M4H1Vmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmS4glUh\|ryP	M{P5OmROW09?	M{HnNmlEPTB;Mj6yOVUh\|ryP	NXTNRXhkOTl7OU[yO\|I>
NCI-H383	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHfIT4p,PSEQvF2=	NGDTcHZFVVOR	NVTacJZCUUN3ME61MlAxKM7:TR?=	NVjGSodzOTl7OU[yO\|I>
JJN3	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUD+OUDPxE1?	NGqzOJJFVVOR	M3nsPGlEPTB;Mj60N\|Mh\|ryP	M2ezRVE6QTl4Mkey
SU.86.86	Mny2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXvzOpVmhjVizszN	MWDEUXNQ	NWPuU5JOUUN3ME2yMlY4OiEQvF2=	Mle2NVk6QTZ{N{K=
H1299	NFzNUYRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHL4OJp,PSEQvF2=	MV7EUXNQ	MmrUTWM2OD53LkCwJO69VQ>?	NIHxS3IyQTl7NkK3Ni=>
MDA-MB-468	M4D4eWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnLBglUh\|ryP	MWfEUXNQ	NEjtOYNKSzVyPUCuOVA1KM7:TR?=	M3;2flE6QTl4Mkey
SW1990	MnHpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYHZTZJlhjVizszN	M3ftcmROW09?	NWrzNodGUUN3ME2wMlgzPiEQvF2=	NF;DXocyQTl7NkK3Ni=>
Calu-6	MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIDyWGN,PSEQvF2=	NYTTcI5iTE2VTx?=	NH7FTnRKSzVyPkWuNFAh\|ryP	NIDyc2YyQTl7NkK3Ni=>
MDA-MB-231	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGnZSFd,PSEQvF2=	NIPJSYxFVVOR	NHrlb4dKSzVyPUGuOlQ5KM7:TR?=	NFvCUoYyQTl7NkK3Ni=>
SW-684	MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUj+OUDPxE1?	MnvMSG1UVw>?	MWnJR\|UxRjVwMECg{txO	MljHNVk6QTZ{N{K=
H209	M37xXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWrMfpg{hjVizszN	NGq4cllFVVOR	NGrWZ\|RKSzVyPUGuNVk{KM7:TR?=	MlS5NVk6QTZ{N{K=
MDA-MB-231T	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlzBglUh\|ryP	M17SXWROW09?	MkTMTWM2OD53LkCwJO69VQ>?	M4HjNlE6QTl4Mkey
HT1080/S	NGH2OGFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXP+OUDPxE1?	NGPNWoJFVVOR	NYTlW5REUUN3ME2wMlU{OSEQvF2=	MXuxPVk6PjJ5Mh?=
H526 0.044	NHjiNWhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mn;iglUh\|ryP	NEPETIlFVVOR	M1zPNGlEPTB;MD6wOFQh\|ryP	NVi0c5I3OTl7OU[yO\|I>
DU4475 2.431	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGTCUnp,PSEQvF2=	MkHJSG1UVw>?	Mn7vTWM2OD1{LkSzNUDPxE1?	M3fNR\|E6QTl4Mkey
HCT116	MlrkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVW1[GN4hjVizszN	NGD5RmNFVVOR	MXHJR\|UxRTBwOEWyJO69VQ>?	NXHGdJFnOTl7OU[yO\|I>
M109	Mk\uS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mn\0glUh\|ryP	MXHEUXNQ	NVfvTVVRUUN3ME2xMlA2PSEQvF2=	M4Kxb\|E6QTl4Mkey
BT549	M2DaT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUP+OUDPxE1?	M{HVTmROW09?	MU\JR\|UxRTFwNkS1JO69VQ>?	NYDIZW5yOTl7OU[yO\|I>
HCT116/VM46	Ml3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHrNT5V,PSEQvF2=	Ml\vSG1UVw>?	NYmx[m9HUUN3ME2xMlcxOiEQvF2=	MlnTNVk6QTZ{N{K=
H460	MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGO1enN,PSEQvF2=	MnvwSG1UVw>?	MoPzTWM2OD1yLke5OUDPxE1?	MXKxPVk6PjJ5Mh?=
MCF-7	MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MV;+OUDPxE1?	NGe0ZnZFVVOR	MnrnTWM2OD1yLkCxOkDPxE1?	M1X1NFE6QTl4Mkey
GEO	MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYPWTllQhjVizszN	NGjZNYVFVVOR	NFXndYJKSzVyPUCuN\|U3KM7:TR?=	NXXjZmsyOTl7OU[yO\|I>
H441 0.646	NWTkS3M4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVX+OUDPxE1?	M1T6XWROW09?	NGHZV49KSzVyPUCuOlQ3KM7:TR?=	MYixPVk6PjJ5Mh?=
MCF-7-807R	NF30[VVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1vpN542KM7:TR?=	NXPkdZBpTE2VTx?=	NEnzXJZKSzVyPUCuOFkh\|ryP	M{PSVFE6QTl4Mkey
Colo205	MlHvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGHRSIN,PSEQvF2=	NXjuW3JkTE2VTx?=	MlLjTWM2OD1yLkGwOEDPxE1?	MXOxPVk6PjJ5Mh?=
H292	NUTHU3dLT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYn0SYFuhjVizszN	NIjC[5hFVVOR	MoHhTWM2OD1yLke4PEDPxE1?	MlHiNVk6QTZ{N{K=
BT474 (S)	M3raT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHTRbJZ,PSEQvF2=	NFvXVIdFVVOR	MnqyTWM2OD1{LkSwN{DPxE1?	M2XxNVE6QTl4Mkey
HT-29	NIiy[VNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlX6glUh\|ryP	NWLscnZ5TE2VTx?=	Ml3KTWM2OD1{LkGwN{DPxE1?	M1W5e\|E6QTl4Mkey
A549	NHS0fWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NU\YUIpOhjVizszN	NYDGTlRoTE2VTx?=	MWjJR\|UxRTBwNke1JO69VQ>?	MnLINVk6QTZ{N{K=
BT474-M1	NUj4b\|FuT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmLjglUh\|ryP	Ml[3SG1UVw>?	MX3JR\|UxRTJwM{[1JO69VQ>?	Mnm4NVk6QTZ{N{K=
SW480	NYjyOFlzT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHm5VZd,PSEQvF2=	M1\VfGROW09?	MVvJR\|UxRjVwMECg{txO	M2r6OlE6QTl4Mkey
L2987	NWr3NYU1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXfpcFRIhjVizszN	MWLEUXNQ	MXrJR\|UxRTBwNESyJO69VQ>?	NYHwNmd4OTl7OU[yO\|I>
AU565	MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4TuXp42KM7:TR?=	MU\EUXNQ	MlTaTWM2OD12Lkm3JO69VQ>?	NXzIV2llOTl7OU[yO\|I>
SW403	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFrnXFN,PSEQvF2=	MX3EUXNQ	MknyTWM2OD1yLkKyJO69VQ>?	M2HFPVE6QTl4Mkey
H1437	NIO0VItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVf+OUDPxE1?	MUPEUXNQ	MU\JR\|UxRTBwNUKzJO69VQ>?	NGf6NmcyQTl7NkK3Ni=>
BT-20	NVPIT2MzT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVr+OUDPxE1?	MkXzSG1UVw>?	NXP1XpM4UUN3ME2zMlU3OiEQvF2=	MV6xPVk6PjJ5Mh?=
Colo320HSR	MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWP+OUDPxE1?	NFnkOnZFVVOR	NETGNVJKSzVyPUCuNFEyKM7:TR?=	NFTsc4EyQTl7NkK3Ni=>
H2087	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFTjXXl,PSEQvF2=	MY\EUXNQ	M3XvU2lEPTB-MT6wNEDPxE1?	MlLJNVk6QTZ{N{K=
HCC1419	M1LINGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1nYfZ42KM7:TR?=	NXX4eJNzTE2VTx?=	NHLEOHpKSzVyPUKuOVE4KM7:TR?=	NFvqcFMyQTl7NkK3Ni=>
WiDr	NWDtdWloT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUL+OUDPxE1?	MX;EUXNQ	NXLFSHpvUUN3ME2wMlA4PiEQvF2=	MWCxPVk6PjJ5Mh?=
H661 0.573	NFnMfIZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHfsVGx,PSEQvF2=	MVrEUXNQ	M{HwVGlEPTB;MD61O\|Mh\|ryP	NUnPWIpVOTl7OU[yO\|I>
HCC-38	NXrw[mlCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4nmdZ42KM7:TR?=	M1LIVmROW09?	MVrJR\|UxRjVwMECg{txO	MkjqNVk6QTZ{N{K=
LS174T	M1fQ[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MW\+OUDPxE1?	NGLsd4FFVVOR	MoLWTWM2OD1yLkWzOUDPxE1?	M2rlTlE6QTl4Mkey
H211	MlPyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUjSeXV5hjVizszN	Mk\iSG1UVw>?	NILTTFhKSzVyPUCuO\|M{KM7:TR?=	M1;Gd\|E6QTl4Mkey
HCC70	NUK2cYZmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkXZglUh\|ryP	M{jKR2ROW09?	NV;w[WV{UUN3ME2xMlU2KM7:TR?=	MmrtNVk6QTZ{N{K=
SW116	MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mm\DglUh\|ryP	M3HNV2ROW09?	MXTJR\|UxRTBwME[3JO69VQ>?	NXjBRWJ[OTl7OU[yO\|I>
H513	M1XxSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2DRXZ42KM7:TR?=	M2PRXmROW09?	M3zTV2lEPTB;ND60OFgh\|ryP	NH7vN3QyQTl7NkK3Ni=>
MDA-MB-157	M1npb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYnxPVU6hjVizszN	NVrpcVhLTE2VTx?=	M2K1[WlEPTB;MD6wN\|Yh\|ryP	M2TFN\|E6QTl4Mkey
H2052	MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3viXJ42KM7:TR?=	NYDuc2ZvTE2VTx?=	NVLHdmNEUUN3ME2xMlA2KM7:TR?=	NI\xO2EyQTl7NkK3Ni=>
MDA-MB-415	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFvHc3J,PSEQvF2=	NI\odotFVVOR	NUCydol[UUN3ME61MlAxKM7:TR?=	M2G2b\|E6QTl4Mkey
DLD-1	MoDZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWX+OUDPxE1?	NFLXWnRFVVOR	MYDJR\|UxRTBwOUC5JO69VQ>?	M1zIRlE6QTl4Mkey
H2595	Ml7FS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlHLglUh\|ryP	MmrHSG1UVw>?	Mn\vTWM2OD12LkS3OUDPxE1?	NFPNXW8yQTl7NkK3Ni=>
MDA-MB-435S	NFjzd4JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWK0W4s2hjVizszN	MVjEUXNQ	MYHJR\|UxRTFwOE[5JO69VQ>?	Ml3uNVk6QTZ{N{K=
HCT15	MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGLqc4R,PSEQvF2=	MX3EUXNQ	M3vT[WlEPTB-MT6wNEDPxE1?	Ml32NVk6QTZ{N{K=
SK-Hep1	M{Xzcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHKxT5V,PSEQvF2=	NXrBUXRNTE2VTx?=	NXHjVYkyUUN3ME2wMlE1PiEQvF2=	NXe4S3I3OTl7OU[yO\|I>
MDA-MB-436	M4i3bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml7PglUh\|ryP	NX;lZXZUTE2VTx?=	NXWxeVZpUUN3ME21MlUxOiEQvF2=	MmTYNVk6QTZ{N{K=
KM12C	NVvzcYhWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoL1glUh\|ryP	MXXEUXNQ	MlzFTWM2OD1yLkC1OEDPxE1?	M4DvNVE6QTl4Mkey
HEPG2	M{PJUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF64d3d,PSEQvF2=	MWfEUXNQ	MV;JR\|UxRTBwMEK1JO69VQ>?	M3zWb\|E6QTl4Mkey
MDA-MB-453	NIT1b\|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NELCTI1,PSEQvF2=	MVrEUXNQ	NWTKb5ZyUUN3ME2xMlg3QSEQvF2=	Mlq3NVk6QTZ{N{K=
KM12SM	NYrjVo9DT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGPDRWJ,PSEQvF2=	NVK2WXRWTE2VTx?=	NGP0W\|JKSzVyPUCuNFU6KM7:TR?=	NGfweZoyQTl7NkK3Ni=>
1483	NVzuVY03T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGTuTVN,PSEQvF2=	NVvkVm5xTE2VTx?=	NWPOdWhUUUN3ME2yMlE6KM7:TR?=	NVryPYU4OTl7OU[yO\|I>
Hs578t	NH72[3pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mni0glUh\|ryP	NUjyfWJUTE2VTx?=	NGG2fpdKSzVyPUGuNlg4KM7:TR?=	NFjVWnoyQTl7NkK3Ni=>
LS180	NVrSS4ZpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVL+OUDPxE1?	NHTwV\|hFVVOR	NHHnRYRKSzVyPUCuOlk3KM7:TR?=	MXqxPVk6PjJ5Mh?=
FaDu	M2r5O2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYqzcZZThjVizszN	NInieYxFVVOR	M13Ob2lEPTB;MT6yO{DPxE1?	M37IOlE6QTl4Mkey
ZR-75-1	M3O0Wmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXTMPYhWhjVizszN	NGTkR2RFVVOR	NX;JZpVYUUN3ME2yMlA5PCEQvF2=	Mn71NVk6QTZ{N{K=
LS513	MnyyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXz4TFZJhjVizszN	MnPBSG1UVw>?	NYD2Wll6UUN3ME2wMlE{PSEQvF2=	MUmxPVk6PjJ5Mh?=
Detroit.562	NFO3NoRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3Tzd542KM7:TR?=	NUjRO5NxTE2VTx?=	MofGTWM2OD1zLkG0JO69VQ>?	M1PUU\|E6QTl4Mkey
ZR-75-30	MnnLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX;+OUDPxE1?	M37sXGROW09?	M2r4SmlEPTB-NT6wNEDPxE1?	NFrzXWYyQTl7NkK3Ni=>
RKO-PM	NWfTNGpuT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnOxglUh\|ryP	NGHXdFJFVVOR	M3;Sb2lEPTB;MD6yN\|Ih\|ryP	M1fiTFE6QTl4Mkey
Cal.27	Mlj5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWj+OUDPxE1?	MWrEUXNQ	M4PpWmlEPTB;MjFOwG0>	NWLBWnZxOTl7OU[yO\|I>
KPL4	NIGw[\|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3Tmcp42KM7:TR?=	NFTie\|BFVVOR	NH7mZo1KSzVyPUGuNlUzKM7:TR?=	MVuxPVk6PjJ5Mh?=
PKO-RM13	M4X4R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWL+OUDPxE1?	MmjYSG1UVw>?	MVfJR\|UxRTBwNEK1JO69VQ>?	NWDuZVhCOTl7OU[yO\|I>
HS.53.T	NInJZpBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWn+OUDPxE1?	MnLYSG1UVw>?	NX;FNmFTUUN3ME2wMlc6KM7:TR?=	MX:xPVk6PjJ5Mh?=
EMT6	MoPiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX[xR3VPhjVizszN	MorFSG1UVw>?	Mmj1TWM2OD1yLkiwOkDPxE1?	NHL2UZYyQTl7NkK3Ni=>
SNU-C1	NFHn[VBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGDWO5R,PSEQvF2=	NWHWcFh5TE2VTx?=	M2rNZ2lEPTB;MD6wNFch\|ryP	MUGxPVk6PjJ5Mh?=
SQCCY1	MmjrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1mxfJ42KM7:TR?=	MVPEUXNQ	Mn3yTWM2OD1yLke5JO69VQ>?	MV:xPVk6PjJ5Mh?=
SW480	NFnWdZlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml\aglUh\|ryP	MVTEUXNQ	NIrzdVFKSzVyPUCuNFM4KM7:TR?=	NULpRmlNOTl7OU[yO\|I>
SCC9	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUX+OUDPxE1?	MYnEUXNQ	NVrlTGg6UUN3ME2wMlc2KM7:TR?=	MVuxPVk6PjJ5Mh?=
SK-LMS-1	M3zBdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{fCRp42KM7:TR?=	NV;pVlNKTE2VTx?=	NFHvbFhKSzVyPUCuOlg4KM7:TR?=	MlHHNVk6QTZ{N{K=
SCC25	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mn7iglUh\|ryP	M2O1S2ROW09?	NVfmT2VSUUN3ME2wMlY5KM7:TR?=	Mlm1NVk6QTZ{N{K=
U87	NIi5bVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4PnPZ42KM7:TR?=	MmfuSG1UVw>?	M4TIWmlEPTB;MD65OUDPxE1?	NI[wdpEyQTl7NkK3Ni=>
SCC15	M4H6c2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVjOV4VVhjVizszN	MoHaSG1UVw>?	NXvhe5lIUUN3ME2wMlY4KM7:TR?=	NYfKUItzOTl7OU[yO\|I>
T98G	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3HLdZ42KM7:TR?=	NV:1[o9iTE2VTx?=	MWXJR\|UxRTFwMkG4JO69VQ>?	MUmxPVk6PjJ5Mh?=
SCC4	M2nQWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWT+OUDPxE1?	NGLIfIpFVVOR	MmntTWM2OD1yLk[zJO69VQ>?	NYHVfphPOTl7OU[yO\|I>
U118	MorZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFn4[Yx,PSEQvF2=	MljWSG1UVw>?	NXTqPJFRUUN3ME2xMlYyQCEQvF2=	NFPiWIcyQTl7NkK3Ni=>
TU167	MmLtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXf+OUDPxE1?	MmS4SG1UVw>?	NH\ve2lKSzVyPUSuOVIh\|ryP	NELJbm0yQTl7NkK3Ni=>
NCI-H727	NVXHW4l7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFjQfJV,OTEkgJtOwG0>	MVHEUXNQ	NV75TlJTUUN3ME20Nlghdk1?	MYGyNFM5PTd2Nx?=
NCI-H720	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mn\LglEx6oDMzszN	M1Xj[WROW09?	NIPtN49KSzVyPUKuPEDPxE1?	MlG5NlA{QDV5NEe=
NCI-H835	NXPOb5JIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkjUglEx6oDMzszN	MYnEUXNQ	MWfJR\|UxRTFizszN	MlrqNlA{QDV5NEe=
NCI-H727	NInLUFdMcW6jc3WgZZN{[Xl?	NHTkfZh,OTEkgJtOwG0>	NVfa[WN1TE2VTx?=	MYDpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=>	MkLjNlA{QDV5NEe=
RD	NULTSYw3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnfOglEx6oDMzszN		M3nnVWlEPTB;MT6xNkDDvU1?	MnznNlEzQTh5NEW=
Rh41	NV75fHcyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUL+NVDjiIsQvF2=		MXTJR\|UxRTBwMEegxtVO	M{PNTFIyOjl6N{S1
Rh18	NWm4[GwyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1Lze54yOOLCit88US=>		Mn;JTWM2OD12Lkm2JOK2VQ>?	NUflO3JUOjF{OUi3OFU>
Rh30	M1y0Umdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFTNWJR,OTEkgJtOwG0>		NVfsV3drUUN3ME2wMlE6KML3TR?=	MYmyNVI6QDd2NR?=
BT-12	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnruglEx6oDMzszN		M2DoT2lEPTB;MD63PEDDvU1?	MYOyNVI6QDd2NR?=
CHLA-266	M1P4Smdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkG1glEx6oDMzszN		MnPiTWM2OD1yLki5JOK2VQ>?	NHXGWJgzOTJ7OEe0OS=>
TC-71	Ml3ZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4qweJ4yOOLCit88US=>		NVK3UVlqUUN3ME2wMlEyKML3TR?=	M{K1WVIyOjl6N{S1
CHLA-9	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1r5dJ4yOOLCit88US=>		NUWxT5I6UUN3ME2wMlEzKML3TR?=	M2\zWFIyOjl6N{S1
CHLA-10	M1K3dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NV[0WGFDhjFy4pEK{txO		M2izUWlEPTB;MD62NkDDvU1?	MnzCNlEzQTh5NEW=
CHLA-258	NIPaNFFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVn+NVDjiIsQvF2=		NGfBb45KSzVyPUCuNlchyrWP	NX:yeZlKOjF{OUi3OFU>
GBM2	NFvw[mVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MW\+NVDjiIsQvF2=		M{LqN2lEPTB;MT60O{DDvU1?	M{fsW\|IyOjl6N{S1
NB-1643	M3S3WWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NV71V3o1hjFy4pEK{txO		MV3JR\|UxRTBwMUKgxtVO	MnXwNlEzQTh5NEW=
NB-EBc1	NEXMUGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NF7Fdoh,OTEkgJtOwG0>		NIXvfnVKSzVyPUCuN\|UhyrWP	MlTyNlEzQTh5NEW=
CHLA-90	NE\i[pVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEPoTVd,OTEkgJtOwG0>		MluyTWM2OD1yLke3JOK2VQ>?	Ml3iNlEzQTh5NEW=
CHLA-136	M3n4W2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mn7qglEx6oDMzszN		M1PrR2lEPTB;MD61NkDDvU1?	NGPOV3MzOTJ7OEe0OS=>
NALM-6	NEfGc4JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWL5VI1NhjFy4pEK{txO		NUHLWlBbUUN3ME2wMlQ6KML3TR?=	NX\Q[G5JOjF{OUi3OFU>
COG-LL-317	NEPWZ49Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NV\5fmtKhjFy4pEK{txO		MnzxTWM2OD1zLkO4JOK2VQ>?	NGD2UYkzOTJ7OEe0OS=>
RS4;11	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkP3glEx6oDMzszN		MVzJR\|UxRTBwM{igxtVO	NVrYOGU6OjF{OUi3OFU>
MOLT-4	NF;reJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIHCNFN,OTEkgJtOwG0>		MYDJR\|UxRTBwNUOgxtVO	MnLnNlEzQTh5NEW=
CCRF-CEM	MmDkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVj+NVDjiIsQvF2=		MV;JR\|UxRTFwMUOgxtVO	NHfkcHEzOTJ7OEe0OS=>
Kasumi-1	NGLlRpFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVz+NVDjiIsQvF2=		MmLvTWM2OD1zLkKgxtVO	MoLiNlEzQTh5NEW=
Karpas-299	M1TnUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4G4cZ4yOOLCit88US=>		MoHLTWM2OD1zLk[0JOK2VQ>?	M1TmZ\|IyOjl6N{S1
Ramos-RA1	M{LxRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVnmb4pNhjFy4pEK{txO		Mmr6TWM2OD1zLkOxJOK2VQ>?	NUjwO4l7OjF{OUi3OFU>
Rh30	M3zqbWZ2dmO2aX;uJIF{e2G7			NWe2dWw{cW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u	MUSyOVkzPTN5OB?=
Rh41	NHT4ZVdHfW6ldHnvckBie3OjeR?=			NUftVmRScW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u	Mlu2NlU6OjV\|N{i=
RD	NYTVRYJbTnWwY4Tpc44h[XO\|YYm=			NV3wPWlTcW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u	M3vvWlI2QTJ3M{e4
A549	MnnQT4lv[XOnIHHzd4F6	NFr1N5YxNjYkgJtOwG0>	MmS0SG1UVw>?	NHXtcW1qdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>?	NVXBUFVxOjZ7Mki1O\|g>
NCI-H358	NUjESZJ3U2mwYYPlJIF{e2G7	NXLvVIlVOC534pEK{txO	MlfwSG1UVw>?	NULtUnZVcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25?	NHHITGwzPjl{OEW3PC=>
A549	M4jHTGZ2dmO2aX;uJIF{e2G7	MlPDNE426oDMzszN	Mn;CSG1UVw>?	MV\jZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	M17GVVI3QTJ6NUe4
NCI-H358	NH3KS4ZHfW6ldHnvckBie3OjeR?=	NWnIVnl7OC534pEK{txO	MW\EUXNQ	NVvXW2E6[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?=	NVHPTId5OjZ7Mki1O\|g>
A549	MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFvXXHR,OTEkgJtOwG0>	NXrDe4c3TE2VTx?=	Ml\hTWM2OD1yLke2JO69VQ>?	NWrXfWVCOjZ7Mki1O\|g>
NCI-H358	MnH3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFT2OnB,OTEkgJtOwG0>	MYPEUXNQ	M1ewR2lEPTB;MT6wPUDPxE1?	M3zJUlI3QTJ6NUe4
A549	NY\RPW5xSXCxcITvd4l{KGG\|c3H5	NHTpZo4xNjYkgJtOwG0>	M4T6[GROW09?	NGTGeWdqdmS3Y3XzJGFxd3C2b4Ppdy=>	NWP0S5REOjZ7Mki1O\|g>
NCI-H358	NEn6XXpCeG:ydH;zbZMh[XO\|YYm=	Mk\BNE426oDMzszN	M13ZeGROW09?	NVzZSlB7cW6mdXPld{BCeG:ydH;zbZM>	NX\KbY1[OjZ7Mki1O\|g>
A549	NHXBV5VHfW6ldHnvckBie3OjeR?=	MlvGNE426oDMzszN	MUXEUXNQ	MU\y[YR2[2W\|IIfveY5lKGOub4P1doU>	NGjpTo0zPjl{OEW3PC=>
NCI-H358	M37sOWZ2dmO2aX;uJIF{e2G7	NFmzZ2sxNjYkgJtOwG0>	NEXwSnlFVVOR	M4\OSJJm\HWlZYOge492dmRiY3zvd5Vz\Q>?	MoX4NlY6Ojh3N{i=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; PubMed: 26136493 Neuro Oncol (C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.	26136493
Growth inhibition assay	Cell viability; PubMed: 30754629 Molecules Response of SK-CO-1 to various drugs and drug combinations.	30754629

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	- Collapse Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	- Collapse Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807